{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:17:57Z","timestamp":1789676277398,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ftd.0b013e31825ee389","type":"journal-article","created":{"date-parts":[[2012,7,7]],"date-time":"2012-07-07T11:47:17Z","timestamp":1341661637000},"page":"440-445","source":"Crossref","is-referenced-by-count":79,"title":["Pharmacokinetic Variability of Four Newer Antiepileptic Drugs, Lamotrigine, Levetiracetam, Oxcarbazepine, and Topiramate"],"prefix":"10.1097","volume":"34","author":[{"given":"Cecilie","family":"Johannessen Landmark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arton","family":"Baftiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Vals\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l G.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisif","family":"Rytter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.07.005","article-title":". Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions.","volume":"87","author":"Johannessen Landmark","year":"2009","journal-title":"Epilepsy Res"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":". Antiepileptic drug use in epilepsya population-based study.","volume":"95","author":"Johannessen Landmark","year":"2011","journal-title":"Epilepsy Res"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second and third generation antiepileptic drugs.","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":". Therapeutic drug monitoring of the newer antiepileptic drugs.","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R7-12-20210129","first-page":"1061","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed Clin Pharmacokinet.","volume":"45","author":"Johannessen","year":"2006","journal-title":""},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","article-title":". Lamotrigine in children and adolescents: the impact on its serum concentrations and on the extent of drug interactions.","volume":"63","author":"Reimers","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-200404000-00010","article-title":"Therapeutic drug monitoring of psychotropic drugs. TDM nouveau.","volume":"26","author":"Bengtsson","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R10-12-20210129","first-page":"2390","article-title":". The WHO Child Growth Standards for children under 5 years in Norwegian.","volume":"127","author":"Baerug","year":"2007","journal-title":"Tidsskr Nor Laegeforen"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00007691-200312000-00008","article-title":". Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response.","volume":"35","author":"Ferrari","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.seizure.2007.02.006","article-title":"Clinical use of antiepileptic drugs at a referral center for epilepsy.","volume":"16","author":"Johannessen Landmark","year":"2007","journal-title":"Seizure"},{"key":"R13-12-20210129","first-page":"573","article-title":"Admission of children to a referral center for epilepsydoes it make a difference Seizure.","volume":"18","author":"Rytter","year":"2009","journal-title":""},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/01.ftd.0000179847.37965.4e","article-title":"Pharmacokinetic variability of new antiepileptic drugs at different ages.","volume":"27","author":"Perucca","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":". Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pediatrneurol.2010.05.008","article-title":"Age and comedications influence levetiracetam pharmacokinetics in children.","volume":"43","author":"Dahlin","year":"2010","journal-title":"Pediatr Neurol"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":". Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/0091270004266617","article-title":". Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.","volume":"44","author":"Rey","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/01.ftd.0000155342.93489.fd","article-title":". 10-hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.","volume":"27","author":"Armijo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":". The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response.","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00004714-200110000-00008","article-title":"Drug glucuronidation in clinical psychopharmacology.","volume":"21","author":"Liston","year":"2001","journal-title":"Clin Psychopharmacol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1528-1167.2011.03217.x","article-title":". The effect of age and comedication on lamotrigine clearance, tolerability and efficacy.","volume":"52","author":"Arif","year":"2011","journal-title":"Epilepsia"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":". Effect of antiepileptic drug comedication on lamotrigine clearance.","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pds.1690","article-title":"Trends and changes in the clinical use of lamotrigine.","volume":"18","author":"Reimers","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":". Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service.","volume":"25","author":"Reimers","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00228-010-0861-y","article-title":". Psychiatric comorbidity in patients with epilepsy: a population-based study.","volume":"66","author":"Karouni","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","article-title":". UGT2B7-161CT polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study.","volume":"32","author":"Blanca Sanchez","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":". The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy.","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res"},{"key":"R29-12-20210129","first-page":"369","article-title":"Combining antiepileptic drugs-rational polytherapy Seizure.","volume":"20","author":"Brodie","year":"2011","journal-title":""},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00007691-200206000-00002","article-title":". Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.","volume":"24","author":"Contin","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","article-title":". Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.","volume":"26","author":"Contin","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"suppl 1","key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1111\/j.1528-1157.1997.tb04512.x","article-title":"Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.","volume":"38","author":"Johannessen","year":"1997","journal-title":"Epilepsia"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.2269","article-title":"Drug safety aspects of antiepileptic drugsfocus on pharmacovigilance.","volume":"21","author":"Johannessen Landmark","year":"2012","journal-title":"Pharmacoepidemol Drug Saf"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31825ee389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:49Z","timestamp":1620952789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201208000-00012"}},"subtitle":["A Comparison of the Impact of Age and Comedication"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31825ee389","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}